Browsing Tag
neuropsychiatry
3 posts
Why next-generation MDMA therapeutics are becoming the new battleground in psychedelic biotech
Why next-generation MDMA therapeutics are reshaping psychedelic biotech strategy, investor expectations, and commercialization competition.
Is bretisilocin the Cymbalta of psychedelic‑inspired psychiatry? What AbbVie’s $1.2 bn bet reveals
AbbVie’s $1.2 B deal for bretisilocin could signal the next era of antidepressants. Could this short‑acting compound become the Cymbalta of psychedelic‑inspired psychiatry?
After AbbVie took bretisilocin, what’s next for Gilgamesh Pharma’s neuropsychiatric pipeline?
Gilgamesh Pharma, newly spun out from the AbbVie deal, holds a promising psychiatric drug pipeline. Here's what the industry should expect next.